Interviews

Bahija Jallal

CEO

Immunocore

2026-03-26

Our technology allows us to look inside the cell, unlocking targets that were previously considered undruggable.

Eric Marcotulli

Co-Founder & CEO

Elysium Health

2026-03-26

Because aging is complex, we don’t expect a single solution, but multiple interventions. We step in where needed, generating clinical data and building the right path to consumers, with the aim of making these discoveries accessible in a preventative, proactive context, rather than forcing them into a traditional disease framework.

Girish Navani

CEO & Co-Founder

eClinicalWorks

2026-03-25

When medical knowledge is democratized across the healthcare delivery system, outcomes improve, and patients live longer, healthier lives. Our challenge over the next year is to make that technology available to all our doctors at an affordable price point. We do not want to build something that only a few can afford. We want to do it at scale, in a way that advances our mission while enabling everyone.

Laurent Hubert

CEO

Biotexia (ABF Ingredients businesses)

2026-03-25

Equally important, bringing together our different competencies means we now have a much larger innovation team. Innovation is at the core of what we do, and by combining clinical research, regulatory, and scientific expertise, we can innovate far more effectively than when these capabilities were spread across three entities.

Dirk Bontridder

CEO

PerkinElmer

2026-03-25

Labs are no longer siloed environments. They are becoming collaborative hubs where pharma companies, biotech investors, tech providers, advisory firms, and others co-create value in ways that were hard to imagine a decade ago.

Scott Pescatore

EVP Rare Diseases Business Unit

Recordati

2026-03-25

Access systems vary widely across markets, but our philosophy is very simple: if a patient needs one of our products, we will find a way to get it to them.

James Atwood

CEO

Opentrons

2026-03-25

There are about 10 scientists right now for every lab robot on the market, and we want to flip that ratio. We want 10 robots for every scientist.

Dawn Sherman

CEO

ProPharma

2026-03-25

We didn’t change the strategy so much as deliberately return to what matters most: our mission to improve patient health and safety and to double-down on the foundations that make our work meaningful.

Mohamed El-Demerdash

President

TELUS Health

2026-03-25

Think of our AI as a highly informed guide, not a decision-maker.

Dr. Larry Schlesinger

President & CEO

Texas Biomedical Research Institute (Texas Biomed)

2026-03-25

My definition of infectious disease is not just about bugs. It is also about the people most vulnerable to infection.

Pagina 3 din 219